The use of recombinant activated factor VII (rFVIIa) in the management of patients with major haemorrhage in military hospitals over the last 5 years.

Recombinant activated factor VII (rFVIIa) has been used in the management of traumatic haemorrhage for a decade. Anecdotally, its use is decreasing. The aim of this study was to define the use of rFVIIa in UK deployed military hospitals over the last 5 years. A retrospective database review was performed, using the Joint Theatre Trauma Registry, for the period January 2006 to June 2011. Data collected included use of rFVIIa, injury severity score (ISS), survival and injury pattern. The temporal trend of rFVIIa use, taking into account the number of severely injured patients presenting during each time period, was then analysed. During the period January 2006 to June 2011, 156 injured patients received rFVIIa. 146 of these (94%) had an ISS >15; there were 45 fatalities. The median ISS among the group receiving rFVIIa was 30, and 20 patients had an ISS in the range 60-75. There was a significant reduction in the use of rFVIIa in the second half of 2010 and the first half of 2011, compared with the previous 12-month period. The use of rFVIIa in UK deployed military hospitals has declined since 2010, which is likely due to a combination of factors, including a change in resuscitation practice in these units, and a change in emphasis of manufacturer's guidance.

Citation

J E Smith. The use of recombinant activated factor VII (rFVIIa) in the management of patients with major haemorrhage in military hospitals over the last 5 years. Emergency medicine journal : EMJ. 2013 Apr;30(4):316-9

Mesh Tags

Substances

PMID: 22609697

search → result